ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On January 25, 2021, Albireo Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for odevixibat for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Exhibit

Number                                     Description
  99.1       Press release dated January 25, 2021
104        Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses